Lataa...

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Huang, Wei-Chien, Hsieh, Yi-Ling, Hung, Chao-Ming, Chien, Pei-Hsuan, Chien, Yu-Fong, Chen, Lei-Chin, Tu, Chih-Yen, Chen, Chia-Hung, Hsu, Sheng-Chieh, Lin, Yueh-Ming, Chen, Yun-Ju
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2013
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877048/
https://ncbi.nlm.nih.gov/pubmed/24391798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0083627
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!